Complexa is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of a new class of drugs to treat metabolic and inflammatory disorders. Nitrated unsaturated fatty acids, generically termed NO2-FA, have been shown to be efficacious in preclinical models of impaired metabolism (diabetes and obesity) and inflammation, including atherosclerosis, restenosis, myocardial infarction, renal disease/failure, hypertension and asthma. This range of commercial options is supported by a broad patent portfolio and provides multiple near- and long-term commercial opportunities for the Company.
The Company is focusing its drug pipeline on several orphan disease conditions characterized by both inflammation and fibrosis. The lead program will be entering Phase 2 clinical trials for focal segmental glomerulosclerosis (FSGS), an orphan kidney disease in children and adolescents, as well as a leading cause of kidney failure in adults. In 2016, the Company will also conduct a proof of concept clinical study in sickle cell crises (SC) which, if successful, will lead to a Phase 2 clinical trial in sickle cell disease. Finally, the Company has identified pulmonary arterial hypertension (PAH) as its third orphan indication and will conduct a Phase 2 study in PAH also in 2016.